The antidepressant-like effect of NevGro® Forte in chronic unpredictable mild stress (CUMS) model of depression in rats

Depression is a leading cause of disability worldwide and it is a major contributor to the overall global burden of disease. Almost 320 million individuals globally are left untreated with depression and it has the highest prevalence. Although there are multiple conventional antidepressant types available, patients are still left untreated due to inadequate pharmacological effectiveness as well as the high rate of remissions, side effects, and patients’ non-compliance. Therefore, this study aims to determine the therapeutic effects of NevGro® Forte. The NevGro® Forte that contains a combination of three types of mushrooms, Lignosus rhinocerotis, Ganoderma lucidum and Hericium erinaceus, has been reported to have the therapeutic potential for alleviating depressive symptoms. Sixty Sprague Dawley rats induced to chronic unpredictable mild stress (CUMS) protocol were orally treated with NevGro® Forte daily for 4 weeks. Histological analysis was performed to probe the role of neurogenesis in mediating the therapeutic effect of NevGro® Forte. Fluoxetine (FLX) was orally administered to validate the neurogenesis-dependent mechanism of NevGro® Forte. The present study exhibited that 4 weeks of NevGro® Forte treatment ameliorated the depressive symptoms in CUMS rat model. There is a significant improvement in body weight, brain’s weight, and increased thickness of the pyramidal layer in the hippocampus following the treatment of NevGro® Forte. Scanning electron microscopy also revealed decreased degeneration characterised by flattened with less dense surface composition in the hippocampus. This research shows a positive outcome of using NevGro® Forte in ameliorating depressive symptoms.